Last reviewed · How we verify
Mozobil
Mozobil is a Small molecule drug developed by University of Washington. It is currently FDA-approved for Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells. Also known as: Plerixafor, AMD 3100, AMD3100, plerixafor.
At a glance
| Generic name | Mozobil |
|---|---|
| Also known as | Plerixafor, AMD 3100, AMD3100, plerixafor |
| Sponsor | University of Washington |
| Target | Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant lymphoma
- Multiple myeloma
- Peripheral Mobilization of Hematopoietic Stem Cells
- Solid malignant tumours
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Injection site reactions
- Headache
- Arthralgia
- Dizziness
- Vomiting
- Hyperleukocytosis
- Abdominal pain
- Hyperhidrosis
- Abdominal distention
Serious adverse events
- Allergic reactions
- Vasovagal reactions
- Orthostatic hypotension
- Syncope
- Dyspnea
- Hypoxia
- Periorbital swelling
- Urticaria
Key clinical trials
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMS (PHASE1, PHASE2)
- Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models (PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1, PHASE2)
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
- CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors (NA)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mozobil CI brief — competitive landscape report
- Mozobil updates RSS · CI watch RSS
- University of Washington portfolio CI
Frequently asked questions about Mozobil
What is Mozobil?
Mozobil is a Small molecule drug developed by University of Washington, indicated for Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells.
What is Mozobil used for?
Mozobil is indicated for Malignant lymphoma, Multiple myeloma, Peripheral Mobilization of Hematopoietic Stem Cells, Solid malignant tumours.
Who makes Mozobil?
Mozobil is developed and marketed by University of Washington (see full University of Washington pipeline at /company/university-of-washington).
Is Mozobil also known as anything else?
Mozobil is also known as Plerixafor, AMD 3100, AMD3100, plerixafor.
What development phase is Mozobil in?
Mozobil is FDA-approved (marketed).
What are the side effects of Mozobil?
Common side effects of Mozobil include Diarrhea, Nausea, Fatigue, Injection site reactions, Headache, Arthralgia. Serious adverse events: Allergic reactions, Vasovagal reactions, Orthostatic hypotension, Syncope.
What does Mozobil target?
Mozobil targets Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2.
Related
- Target: All drugs targeting Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2
- Manufacturer: University of Washington — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Malignant lymphoma
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for Peripheral Mobilization of Hematopoietic Stem Cells
- Also known as: Plerixafor, AMD 3100, AMD3100, plerixafor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing